Montag A & Associates Inc. increased its holdings in AbbVie Inc. (NYSE:ABBV) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,349 shares of the company’s stock after acquiring an additional 253 shares during the quarter. Montag A & Associates Inc.’s holdings in AbbVie were worth $5,101,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in ABBV. Acropolis Investment Management LLC acquired a new position in AbbVie in the 2nd quarter valued at $106,000. Franklin Parlapiano Turner & Welch LLC acquired a new position in AbbVie in the 1st quarter valued at $108,000. Atwood & Palmer Inc. increased its stake in AbbVie by 1,333.3% in the 1st quarter. Atwood & Palmer Inc. now owns 2,150 shares of the company’s stock valued at $140,000 after buying an additional 2,000 shares during the period. Tradewinds Capital Management LLC increased its stake in AbbVie by 87.2% in the 1st quarter. Tradewinds Capital Management LLC now owns 2,269 shares of the company’s stock valued at $148,000 after buying an additional 1,057 shares during the period. Finally, Exane Asset Management acquired a new position in AbbVie in the 2nd quarter valued at $181,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have issued reports on ABBV shares. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price objective on the stock in a research note on Tuesday, October 17th. BidaskClub cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 25th. Vetr raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $76.28 price objective on the stock in a research note on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $100.00 price objective (up from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $107.00 price objective (up from $94.00) on shares of AbbVie in a research note on Friday, September 15th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $93.68.
Shares of AbbVie Inc. (ABBV) opened at $95.12 on Tuesday. AbbVie Inc. has a 1 year low of $58.60 and a 1 year high of $98.26. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. The company has a market cap of $152,347.31, a PE ratio of 17.97, a P/E/G ratio of 1.32 and a beta of 1.51.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. During the same period in the previous year, the firm earned $1.21 EPS. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. analysts anticipate that AbbVie Inc. will post 5.55 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.99%. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date is Thursday, January 11th. AbbVie’s dividend payout ratio is 62.29%.
In other news, insider Henry O. Gosebruch sold 18,300 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the completion of the transaction, the insider now owns 81,287 shares of the company’s stock, valued at approximately $7,360,537.85. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael Severino sold 25,633 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the transaction, the executive vice president now directly owns 114,922 shares of the company’s stock, valued at approximately $10,881,964.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 58,932 shares of company stock worth $5,379,432. 0.23% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/14/montag-a-associates-inc-acquires-253-shares-of-abbvie-inc-abbv.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.